Core Viewpoint - A securities class action lawsuit has been filed against former executives of Zynex, Inc. for allegedly misleading investors about the company's growth, which was reportedly driven by fraudulent practices [1][2]. Summary of Allegations - The lawsuit claims that Zynex engaged in an "oversupplying scheme," shipping medically unnecessary supplies to inflate billings, leading to significant financial repercussions including an $85 million forfeiture to the Tricare military health program [2][6]. - Allegations include that Zynex's reported revenue growth was not organic but rather a result of predatory billing practices, despite warnings from major insurers [3][6]. - The company faced criminal charges against its former leadership, including the indictment of former CEO Thomas Sandgaard and former COO Anna Lucsok for health care and securities fraud [6]. Financial Impact - Zynex's revenue was significantly impacted, with the company forced to file for Chapter 11 bankruptcy and subsequently delisted from the Nasdaq, resulting in a near-total loss of value for common equity holders [6]. - Tricare, which represented 25% of Zynex's revenue, suspended payments in March 2025, contributing to the company's financial decline [6]. Legal Proceedings - The class action lawsuit seeks to recover losses for all individuals and entities that purchased Zynex securities during the class period from February 25, 2021, to December 15, 2025 [1][5]. - Investors have until April 21, 2026, to request appointment as Lead Plaintiff in the lawsuit [5]. Whistleblower Information - Individuals with non-public information regarding Zynex are encouraged to consider their options to assist in the investigation or utilize the SEC Whistleblower program, which offers rewards for original information leading to successful recoveries [5].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Zynex, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1] Company Overview - Zynex, Inc. is facing scrutiny for allegedly inflating its stock price through false and misleading statements regarding its financial performance and operational practices [6] - The company reportedly engaged in a systemic "oversupplying scheme," shipping excessive quantities of supplies and billing insurers for inflated amounts [6] Financial Impact - The misconduct was revealed on March 11, 2025, when Zynex announced a significant revenue shortfall attributed to slower payments from insurers, particularly Tricare, which accounts for 20-25% of its annual revenue [6] - Following the announcement, Zynex's stock price dropped by $3.59 per share, or 51.3%, closing at $3.41 per share, resulting in a substantial loss of shareholder value [6]

Core Viewpoint - Zynex, Inc. is under investigation for potential claims related to a class action complaint alleging that the company's board of directors breached their fiduciary duties by misleading investors about financial performance and operational practices [1][2]. Summary by Relevant Sections Allegations of Misconduct - The complaint claims that Zynex's management engaged in practices that artificially inflated the company's stock price through false statements regarding financial performance and compliance with insurance reimbursement policies [2]. - It is alleged that Zynex operated a systemic "oversupplying scheme," shipping excessive quantities of supplies to patients and billing insurers significantly more than necessary [2]. Financial Impact and Regulatory Scrutiny - The extent of Zynex's misconduct was revealed on March 11, 2025, when the company announced a revenue shortfall due to slower payments from insurers, particularly Tricare, which accounted for 20-25% of its annual revenue [3]. - Following the announcement, Zynex's stock price fell by $3.59 per share, or 51.3%, closing at $3.41 per share, indicating a severe loss of shareholder value and highlighting the company's exposure to regulatory and financial risks [4].